SCHEMBL4940981

SCHEMBL4940981

CC(C)(C)OC(=O)N1CCN(c2ccc(C(=O)C(F)(F)F)cc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.61
LMNA P02545 2/20 0.61
ALDH1A1 P00352 2/20 0.61
GPR119 Q8TDV5 8/20 0.58
KMT2A Q03164 5/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
MEN1 O00255 4/20 0.57
CYP2C19 P33261 1/20 0.57
HTT P42858 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
NAMPT P43490 1/20 0.53
PDK2 Q15119 1/20 0.53
ESRRB O95718 1/20 0.50
ESR1 P03372 1/20 0.50
ESRRA P11474 1/20 0.50
ESRRG P62508 1/20 0.50
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26054723 0.89 MAPT (0.64) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL5573222 0.87 MAPT (0.76) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL23228892 0.85 GPR119 (0.55) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL63633 0.85 MAPT (0.65) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL1481563 0.85 GPR119 (0.78) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL14452743 0.84 SMN1; SMN2 (0.57) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL13218466 0.83 GPR119 (0.79) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL2453801 0.83 MAPT (0.64) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL1459696 0.83 MAPT (0.64) MAPTLMNAALDH1A1GPR119KMT2A
SCHEMBL4038648 0.83 MAPT (0.64) MAPTLMNAALDH1A1GPR119KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
EP-1858869-A1 ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094842-A1 ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed
WO-2006094842-A1 ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors SLC1A1, SLC6A7, SLC1A2 MAPT 762/4885LMNA 4248/4885ALDH1A1 1291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.